Riluzole hydrochloride manufacturers
|
| | Riluzole hydrochloride Basic information |
| Product Name: | Riluzole hydrochloride | | Synonyms: | 2-AMINO-6-TRIFLUOROMETHOXYBENZOTHIAZOLE HYDROCHLORIDE;RILUZOLE HCL;RILUZOLE HYDROCHLORIDE;6-(Trifluoromethoxy)benzo[d]thiazol-2-amine hydrochloride;Riluzole (PK 26124), GABA uptake inhibitor | | CAS: | 850608-87-6 | | MF: | C8H6ClF3N2OS | | MW: | 270.66 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File |  |
| | Riluzole hydrochloride Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMF: 30 mg/mL; DMSO: 30 mg/mL; Ethanol: 30 mg/mL; Ethanol:PBS (pH7.2)(1:20): 0.04 mg/mL; Water: Soluble | | form | A solid | | color | White |
| | Riluzole hydrochloride Usage And Synthesis |
| Description | Riluzole is a benzothiazole derivative with anti-excitotoxic effects that acts by blocking the presynaptic release of glutamate, indirectly antagonizing glutamate receptors, and inactivating neuronal voltage-gated Na+ channels (ED50 = 2.3 μM). Riluzole suppresses glutamate-induced seizures in rats at an ED50 value of 3.2 mg/kg and displays neuroprotective effects in hypoxic animals at an ED50 value of 4 mg/kg. Formulations containing riluzole have been explored as therapeutics for slowing disease progression of amyotrophic lateral sclerosis. | | Uses | Riluzole is a benzothiazole derivative with anti-excitotoxic effects that acts by blocking the presynaptic release of glutamate, indirectly antagonizing glutamate receptors, and inactivating neuronal voltage-gated Na+ channels (ED50 = 2.3 μM). Riluzole suppresses glutamate-induced seizures in rats at an ED50 value of 3.2 mg/kg and displays neuroprotective effects in hypoxic animals at an ED50 value of 4 mg/kg. Riluzole has been explored as a therapeutic for slowing disease progression of amyotrophic lateral sclerosis. | | Uses | Riluzole is a glutamate release inhibitor. It also induces caspase-dependent apoptosis and suppress cell proliferation in human heptocellular carcinoma. Riluzole is a neuroprotective and a anticancer agent. | | in vivo | In normal na ve rats, systemic injection of Riluzole hydrochloride (8 mg/kg, i.p.; n=6 rats) decreases the duration of ultrasonic but not audible vocalizations evoked by noxious stimulation of the knee joint compare to vehicle tested in the same rats (P<0.05). Systemic application of Riluzole hydrochloride (8 mg/kg, i.p.; n=19 rats) decreases the vocalizations of arthritic rats compare to predrug and vehicle significantly (P<0.05 to 0.001). Riluzole hydrochloride administered into the CeA significantly decreases the duration of audible and ultrasonic vocalizations evoked by noxious stimulation of the knee compare to predrug values (n=8 rats; P<0.05 to 0.01)[2]. | | storage | Room temperature | | References | [1] B C CHEAH. Riluzole, neuroprotection and amyotrophic lateral sclerosis.[J]. Current medicinal chemistry, 2010, 17 18: 1942-199. DOI: 10.2174/092986710791163939 |
| | Riluzole hydrochloride Preparation Products And Raw materials |
|